Hosted on MSN2d
AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?
AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of ...
Crain's Chicago Business1d
Despite $3.5B impairment charge on failed Cerevel drug, AbbVie still sees potential
The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...
AbbVie Unusual Options Activity For January 10
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25
Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...
AbbVie Has Immense Cash Flow Potential
AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.
Pharmaceutical Technology17d
Onabotulinumtoxin A by AbbVie for Unspecified Musculoskeletal Disorders: Likelihood of Approval
Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.
pharmaphorum8d
Allergan gets FDA okay for paediatric Botox use
The extension of Botox’s use is also good news for AbbVie, which is in the process of acquiring Allergan in a $63 billion deal. The pivotal element of that deal is bolting on Botox’ $3.6 ...
Baby boomers and ‘Ozempic face’ drive injectables craze
Baby boomers and users of weight loss drugs suffering from “facial sagging” are flocking to injectable aesthetic treatments ...
Prevention29d
Meet Two Women Who Learned to Manage Their Chronic Migraine
Whetstone’s doctor also recommended BOTOX for Chronic Migraine, a product of AbbVie, to help reach her treatment goals. “It allowed me to manage my disease,” she says. Both Whetstone and ...